Tuesday, October 25, 2022 5:39:34 PM
There’s no doubt that several companies are interested in acquiring NWBO. The problem is that the controlling interests have no intention of selling the company at anywhere near the current price, even with a hefty premium added. BP are not traders and will not start buying shares on the open market. That’s not what they do. They will have to wait and see what happens and take it from there. If the share price gets to a level where the added premium (50-150%) makes sense for both parties, I am certain we will see some activity. I don’t know what the intention is in regard to a sale or partnership, but until we see some news and movement in the application process and share price, I doubt we will get any information about this.
When I started investing in NWBO in early 2020, I was recommended it by someone who worked closely with management as an outside merchant and he told me that LP was never going to do anything that would risk DCVax-L getting to market. I understand that we are now so far into that process that the scenario of it getting ‘shelved’ is non-existent, but just wanted to mention it anyway.
When I started investing in NWBO in early 2020, I was recommended it by someone who worked closely with management as an outside merchant and he told me that LP was never going to do anything that would risk DCVax-L getting to market. I understand that we are now so far into that process that the scenario of it getting ‘shelved’ is non-existent, but just wanted to mention it anyway.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
